Scholarlink

The COVID-19 pandemic, originating from SARS-CoV-2 has threatened global health severely. The efforts to combat it involve extensive vaccine development using diverse methods including whole virus, protein-based, and nucleic acid (DNA and RNA) technologies. The mRNA vaccine, a notable advancement, gained emergency approval, signifying a significant milestone in nucleic acid vaccination. These vaccines aim to provide effective immunization against the virus, crucial in facing the pandemic’s unprecedented global threat. This chapter reports a comprehensive literature review discussing how new technology of mRNA vaccine can be utilized in the manufacturing process of COVID-19 vaccines. The mRNA COVID-19 vaccines such as Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273 have revolutionized the global pandemic response. They employ mRNA to instruct cells to generate immune responses. The mechanism involves mRNA encoding specific antigens, inducing robust immune responses against targeted diseases such as COVID-19. In terms of formulation, mRNA utilizes lipid nanoparticles to enter the cells, initiating protein synthesis and immune responses, crucial for preventing disease onset. COVID-19 mRNA vaccine development, distribution strategies, production processes, and comparisons with other vaccine’s technology were discussed comprehensively. Prioritization of vaccine distribution is generally given to health and social care workers, residents and staff of residential nursing homes for the elderly, and elderly people. In conclusion, mRNA plays an important role in rapidly developing COVID-19 vaccines. The reliability of data obtained to conduct the study was the limitation identified. However, to further develop understanding, research must extend beyond to explore more strategies to improve and optimize the mRNA technology. Adverse events identification should be continuously monitored and evaluated during the post-administration of mRNA vaccines.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Emerging the Potential of mRNA Technology in Covid-19 Vaccine Manufacturing

  • 章节

  • 发表日期：

    2026年

查看全文
  • Muhammad Taher,
  • Muhammad Imtiaaz Aziman Muhd Rosdi,
  • Muhammad Syahmil Irsyad Mohd Nizam Nur,
  • Qurratu Ain Zainuri,
  • Nur Shafira Izzatie Mohd Nor Shokri,
  • Nureen Hannani Mohd Pazli,
  • Deny Susanti,
  • Erizal Zaini,
  • Junaidi Khotib

摘要

The COVID-19 pandemic, originating from SARS-CoV-2 has threatened global health severely. The efforts to combat it involve extensive vaccine development using diverse methods including whole virus, protein-based, and nucleic acid (DNA and RNA) technologies. The mRNA vaccine, a notable advancement, gained emergency approval, signifying a significant milestone in nucleic acid vaccination. These vaccines aim to provide effective immunization against the virus, crucial in facing the pandemic’s unprecedented global threat. This chapter reports a comprehensive literature review discussing how new technology of mRNA vaccine can be utilized in the manufacturing process of COVID-19 vaccines. The mRNA COVID-19 vaccines such as Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273 have revolutionized the global pandemic response. They employ mRNA to instruct cells to generate immune responses. The mechanism involves mRNA encoding specific antigens, inducing robust immune responses against targeted diseases such as COVID-19. In terms of formulation, mRNA utilizes lipid nanoparticles to enter the cells, initiating protein synthesis and immune responses, crucial for preventing disease onset. COVID-19 mRNA vaccine development, distribution strategies, production processes, and comparisons with other vaccine’s technology were discussed comprehensively. Prioritization of vaccine distribution is generally given to health and social care workers, residents and staff of residential nursing homes for the elderly, and elderly people. In conclusion, mRNA plays an important role in rapidly developing COVID-19 vaccines. The reliability of data obtained to conduct the study was the limitation identified. However, to further develop understanding, research must extend beyond to explore more strategies to improve and optimize the mRNA technology. Adverse events identification should be continuously monitored and evaluated during the post-administration of mRNA vaccines.